Two Indian manufacturers cited by FDA for data integrity issues

By Zachary Brennan

- Last updated on GMT

Related tags Evaluation Fda

Two Indian manufacturers cited by FDA for data integrity issues
Bangalore, India-based Apotex and Verna, India-based Micro Labs both received warning letters last month from the US FDA detailing data integrity questions linked to their quality systems.

The US FDA said the examples outlined in the letter for Apotex​ “are of serious CGMP violations demonstrating that your quality system does not adequately ensure the accuracy and integrity of the data generated at your facility to ensure the safety, effectiveness, and quality of the drug products you manufacture. We found that your quality system failed to ensure the adequate investigation and resolution of quality failures​.” 

The history of the company’s working with the FDA to resolve cGMP violations is extensive. In April, the agency banned the facility​ from importing its products to the US, while back in March 2012, Apotex sued the agency​ over a similar import alert.

The FDA most recently takes issue with Apotex’s response to the violations uncovered during the June inspection. “Your response and comments focus primarily on the issue of intent, and do not adequately address the seriousness of the CGMP violations found during the inspection​,” the agency says.

QC personnel from Apotex were also cited for creating unauthorized folders on laboratory computerized systems without appropriate oversight.  

FDA’s concern pertains to the practice of disregarding failing results, conducting trial injections and retesting products without any investigation. We are also concerned that you do not have documentation to support your decision to retest samples of lots that had initially failed to meet specifications, and you allowed manufacturing activities to occur without the oversight of your quality unit​,” the agency says.

The agency says it’s seeking “a detailed description of all computerized systems in your facility used for testing drugs​,” as well as “information on each electronic folder that was not created pursuant to a valid SOP [standard operating procedure] and an assessment of every file in each such folder​.” 

Apotex spokesman Steve Giuli told us: “Receipt of a warning letter after issuance of an import alert is standard practice by the FDA. To ensure all of our facilities continue to meet the highest quality and safety standards Apotex has dedicated significant resources to further reinforce our culture of quality. We have implemented improved training programs and applied new procedures to mitigate the risk of employee error through enhanced quality assurance measures and third-party validators. Customers can remain confident that our medicines are safe, effective, and will remain available on a reliable schedule​.”

Micro Labs

Similarly to Apotex, Micro was cited with data integrity issues when an inspection from May “identified laboratory test records that you did not review and evaluate in making batch release decisions.  These records contained uninvestigated, out of specification (OOS) data​,” the FDA said in its letter​.

The company was also cited, just as Apotex was, for using “trial​” sample injection even after the approval of a new SOP that the company’s quality system and management failed to detect and correct. 

The agency “strongly​” recommends that Micro hires a qualified third party auditor/consultant to help the company come into compliance with regulations and statutory authorities. 

Micro Labs did not respond to a request for comment.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...